AI-Derived Score to Predict Effort Intolerance and Adverse Outcomes Across the Heart Failure Spectrum.

Del Punta L; University of Pisa, Pisa, Italy.
Moura-Ferreira S; Georgiopoulos G; Mastoras G; et al

Journal of Cardiac Failure. 32(11):1957-1969, 2026 Nov.

AIMS: To develop and externally validate an artificial intelligence
(AI)-driven model to predict effort intolerance (ie, peak oxygen uptake
[VO2] <16 mL/kg/min) in patients at risk for or with established heart
failure (HF).

METHODS: We enrolled a consecutive sample of adults referred for dyspnea
or suspected HF. The derivation cohort (Pisa, Italy) included 1333
participants: 351 with reduced (<50%, HFrEF), 371 with preserved (>=50%,
HFpEF) left ventricular ejection fraction (LVEF), and 611 with
cardiovascular risk factors and/or structural heart disease without overt
HF (stages A, B); the external validation cohort (Hasselt, Belgium)
included 1101 participants. All participants underwent clinical
evaluation, laboratory tests, rest echocardiography, and cardiopulmonary
exercise testing.

RESULTS: A neural network including age, sex, body mass index (BMI),
hemoglobin, left ventricular systolic mitral annulus tissue velocity (LV
S’), systolic pulmonary artery pressure (sPAP), and beta-blocker therapy
achieved the best discrimination (AUC 0.86 +/- 0.01 in derivation; 0.76
+/- 0.06 in validation). A simplified 4-variable AI-VO2 score (BMI,
hemoglobin, LV S’, sPAP) showed good performance (AUC 0.79 +/- 0.05) and
independently predicted hospitalization due to HF or all-cause death
(adjusted HR 1.06 per point; 95% CI 1.03-1.10) in the derivation cohort.
External validation confirmed the predictive and prognostic performance
(AUC 0.73 +/- 0.02; unadjusted HR 1.18 per point, 95% CI 1.13-1.24).
Score-based risk strata (<10, low; 10-13, intermediate; >13, high) showed
a significant prognostic gradient (log-rank chi2=36.8; P < 0.001).

CONCLUSION: The AI-VO2 score is a clinically interpretable, externally
validated tool for identifying patients with effort intolerance and
adverse outcomes across the HF spectrum, supporting personalized risk
stratification and management.